The agreement covers Hong Kong, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Under the deal, DKSH will manage the commercialization of Qutenza, Vimovo, Palexia, and Zomig, including navigating local regulatory approvals, marketing, and distribution. Grünenthal will continue to manufacture the products through its global network.

This partnership builds on a 2023 collaboration between the two companies. By leveraging DKSH’s regional infrastructure, Grünenthal intends to accelerate the availability of its portfolio in territories where access to specialized care remains inconsistent. For millions in the region suffering from chronic conditions, the introduction of these therapies represents a significant shift in available treatment options.